# A Study of SHR-4394 Injection in Subjects With Prostate Cancer

> **NCT06783829** · PHASE1 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 240 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** SHR4394

## Key facts

- **NCT ID:** NCT06783829
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-22
- **Primary completion:** 2027-03
- **Final completion:** 2027-03
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06783829

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06783829, "A Study of SHR-4394 Injection in Subjects With Prostate Cancer". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06783829. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*